Compare Davita Inc (DVA) vs Fiverr International Ltd (FVRR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Fiverr International Ltd — how do they compare? Davita Inc trades at $231.11 (market cap $14.92B), while Fiverr International Ltd trades at $11.26 (market cap $397.97M). The key difference: Davita Inc is far larger — about 37.5× Fiverr International Ltd's market cap, and Davita Inc is trading nearer its 52-week high, Fiverr International Ltd nearer its low. Which is the better fit depends on your goals.
| DVA | FVRR | |
|---|---|---|
Market Cap | $14.92B | $397.97M |
Sector | Health | Industrials |
52-Week High | $235.71 | $26.67 |
52-Week Low | $103.87 | $9.62 |
Enterprise Value | $27.47B | $128.57M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
Fiverr International (FVRR) trades at $11.27, up 2.08% today, with a bullish technical signal from moving averages. Revenue grew to $430.91M in 2025, with net income reaching $20.98M and a 4.86% margin. The stock appears undervalued with a P/E of 14.64 and P/S of 0.97. Recent news highlights Fiverr's upcoming Q2 2026 earnings and a surge in demand for AI coding specialists, though the stock remains near its 52-week low, down 66% from its high.
The outlook is mixed: strong profitability metrics and low valuation ratios present a potential opportunity, but risks include declining active buyers, ongoing legal investigations, and volatile cash flows. Analyst consensus leans neutral with 41% buy ratings, suggesting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Fiverr International Ltd
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Writing and Translation, and Video and Animation among others.
Read more on FVRR →
